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Summary The threat of smallpox as a biological weapon has spurred efforts to
create stockpiles of vaccine for emergency preparedness. In lieu of preparing vaccine
in animal skin (the original method), we cloned vaccinia virus (New York City Board of
Health strain, Dryvax1) by plaque purification and amplified the clone in cell culture.
The overarching goal was to produce a modern vaccine that was equivalent to the
currently licensed Dryvax1 in its preclinical and clinical properties, and could thus
reliably protect humans against smallpox. A variety of clones were evaluated, and
many were unacceptably virulent in animal models. One clonal virus (ACAM1000) was
selected and produced at clinical grade in MRC-5 human diploid cells. ACAM1000 was
comparable to Dryvax1 in immunogenicity and protective activity but was less
neurovirulent for mice and nonhuman primates. To meet requirements for large
quantities of vaccine after the events of September 11th 2001, the ACAM1000 master
virus seed was used to prepare vaccine (designated ACAM2000) at large scale in Vero
cells under serum-free conditions. The genomes of ACAM1000 and ACAM2000 had
identical nucleotide sequences, and the vaccines had comparable biological pheno-
types. ACAM1000 and ACAM2000 were evaluated in three Phase 1 clinical trials. The
vaccines produced major cutaneous reactions and evoked neutralizing antibody and
cell-mediated immune responses in the vast majority of subjects and had a reacto-
genicity profile similar to that of Dryvax1.ished by Elsevier Ltd. All# 2004 International Society for Infectious Diseases. Publ
rights reserved.* Corresponding author. Tel.: +1 617 494 1339; fax: +1 617 494 0927.
E-mail address: tom.monath@acambis.com (T.P. Monath).
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In 1980, the World health Organization (WHO)
declared that smallpox had been eradicated from
the face of the Earth. This was achieved by an inten-
sified international program of surveillance and vac-
cination. In 1980, there were uncertainties about the
potential reappearance of the disease, and prepara-
tions were made for a large reserve stockpile of
vaccine (200 million doses) to be held in Geneva
and New Delhi. At the time, there was minimal con-
cern about smallpox as a bioweapon. By1984only two
controlled repositories of variola strains remained (in
MoscowandAtlanta),making attribution clear in case
of a biological attack. Moreover the high prevalence
of vaccine immunity was thought to be a disincentive
to the use of variola as a weapon. By 1986, in the
absence of any recrudescence of smallpox, WHO
reduced its vaccine repository to approximately
500,000 doses. Moreover, smallpox vaccine manufac-
turing had virtually ceased worldwide in the absence
of vaccination programs and any commercial incen-
tive for production.
Smallpox had virtually disappeared from the Uni-
ted States and Europe (except for occasional
imported cases) a decade before global eradication.
With the diminishing threat of smallpox and
increased focus on adverse events,1,2 vaccination
in the United States was discontinued in 1972 for the
general public and in 1989 for military personnel.
With each passing year, the population thus became
increasingly vulnerable to the virus. In the mid
1990s, the United States Government became
alarmed about the threat of smallpox as an agent
of biological terrorism.3 The concern stemmed from
revelations by defectors from the former Soviet
Union, especially Kanatjan Alibekov (Ken Alibek).4
He disclosed the existence of a sophisticated pro-
gram beginning shortly after World War II and cul-
minating in the 1980s with large-scale production of
a virulent variola strain, and positioning of strategic
long-range bombers and SS-18 multiple warhead
intercontinental missiles armed with munitions con-
taining the virus. Although the Soviet biological
program was officially renounced by President Yelt-
zin in 1991, destruction of these weapons has never
been verified, and new concerns have arisen about
proliferation of smallpox stocks in other countries
having adversarial relations with the West. Between
Alibek’s defection in 1992 and 1998, United States
policy was shaped accordingly. In 1998, President
Clinton announced a program to provide counter-
measures, including a stockpile of vaccines. Only 15
million doses of smallpox vaccine remained in the
US, and these doses had been manufactured 20
years earlier.In July, 1999, the Centers for Disease Control and
Prevention (CDC) solicited expressions of interest
from industry in manufacturing a 40 million dose
stockpile of a modern cell culture smallpox vaccine,
and in September 2000, a contract for vaccine pro-
duction was awarded to Acambis. After the events of
September 11, 2001, the terms of the original con-
tract were modified to increase deliverable doses
from 40 to 54 million. In November 2001, Acambis
successfully competed for and was awarded a second
contract for an additional 155 million doses of vac-
cine, bringing the total requirement to 209 million
doses. Both CDC contracts specified that the new
vaccine be delivered in the shortest possible time-
frame and that it be licensed by the US Food & Drug
Administration (FDA) based on successful clinical
trials. The Government’s intention was to have ‘‘1
dose available for every citizen’’. The balance of
doses between the Acambis contracts and the US
population was to be drawn from the original stock-
pile of 15 million doses of licensed vaccine [Dryvax1
(NewYork City Board of Health strain),Wyeth Labora-
tories], which (based on new clinical trial data5,6)
could be diluted 1:5 for administration to humans
in an emergency. In order to deliver such a large
quantity of vaccine, Acambis partnered with Baxter
BioScience, which had large-scale bioreactor capa-
city at its facilities near Vienna, Austria.Development of a new cell culture
vaccine
First generation smallpox vaccines are manufactured
from lymph collected from the skin of live animals
(most often calves or sheep) that have been scarified
withvacciniavirus.Thismethodofmanufacturecame
into widespread use in the second half of the 19th
Century. Although first generation vaccines are still
made in the Netherlands, Russia and China, this
method of manufacture is highly undesirable, parti-
cularly with respect to control of adventitious viruses
and in light of advances in technology. Since vaccinia
virus grows to high titers in a variety of cell culture
systems acceptable for use in manufacturing human
vaccines, the obvious objective was to manufacture
the vaccine in an approved cell bank, preferably in
continuous cells that had been controlled for adven-
titious agents and tumorgenicity. At the time the
project began, there had been several successful
historical attempts to produce cell culture smallpox
vaccines, including viruses propagated in primary
rabbit kidney cells7,8 and in continuous MRC-5 human
diploid lung fibroblast cells.9
A critical decision at initiation of the project was
whether or not to establish a biological clone or to
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culture without cloning. The benefits of cloning
appeared to outweigh the recognized risk that a
clonal virus population may differ biologically from
the ‘genetic swarm’ represented by the animal-skin
vaccine.10 Because it would not be possible to con-
duct field tests for efficacy, the new vaccine would
need to match the licensed vaccine (Dryvax1) as
closely as possible in preclinical tests for safety,
immunogenicity, and protective activity and in clin-
ical trials for safety and immunogenicity.
The initial development of a suitable vaccine
candidate (designated ACAM1000) was recently
described by Weltzin et al.10 They isolated and char-
acterized multiple clonal viruses and also passed the
uncloned virus population in MRC-5 cells. Cloning or
passage commenced by pooling of ten 100-dose vials
from each of 3 different production lots of Dryvax1.
Six clones were isolated by 3 sequential plaque-
purifications at terminal dilution and amplified to
produce virus stocks at MRC-5 passage (P) 5. The
uncloned virus was produced by 3 passages in MRC-
5 cells at a multiplicity of infection (MOI) of 0.001
plaque-forming units (pfu)/cell.
Although the clones were derived by plaque pick-
ing at terminal dilution and should represent the
majority virus population in Dryvax1, significant
differences among them were observed.10 As noted
below, Clones 1, 3, and 5 and the uncloned virus had
virulence properties that were unacceptable for
consideration as vaccine candidates. The results
with the uncloned virus demonstrated that it would
have been undesirable to manufacture by simply
passing the original calf-skin virus in cell culture.Preclinical safety in animal models
To determine if the viruses differed from Dryvax1 in
their ability to cause pock lesions in skin, the clonalTable 1 50% and 90% Lethal Doses (LD) of Dryvax1 and vacci
of 2.3 log10 plaque-forming units (pfu) inoculated by the in
Experiment Virus LD50/0.0
1 Dryvax1 1.6
Polyclonal <1.3
Clone 1 <2.3
2 Dryvax1 <1.3
Clone 2 (ACAM1000) 1.5
Clone 3 <1.3
Clone 4 2.6
3 Dryvax1 2.2
Clone 5 <1.3
Clone 6 1.6
* Significantly different from Dryvax (p < 0.05, Kaplan—Meier suand uncloned vaccine candidates were inoculated by
the intradermal route in rabbits. Rabbits were inocu-
lated in the paravertebral area with tenfold dilutions
of a candidate virus and along the opposite side with
graded doses of Dryvax1. On Day 8, the diameter of
erythema and of the central lesion (ulcer) were mea-
sured. Dryvax1 produced a maximum erythema of
20 mm and a maximum central lesion diameter of
3 mm. Lesion size was greater than Dryvax1 for
Clones 1, 3 and 5 and for the polyclonal virus,whereas
Clones 2, 4, and 6 produced either no central lesions,
or lesions that were similar to Dryvax1.
It has long been known that vaccinia strains differ
with respect to neurovirulence in infant mice. The 6
clonal and 1 uncloned vaccine candidates were
therefore compared to Dryvax1 by intracerebral
(IC) inoculation of suckling mice with log10 dilutions
of virus. The same four viruses that had exhibited
excessive virulence in rabbit skin (Clones 1, 3, and 5,
and the polyclonal virus) were significantly more
neurovirulent than Dryvax1 (p < 0.05, Kaplan—
Meier survival distribution, log rank test), whereas
Clones 2, 4, and 6 were similar to Dryvax1 or less
virulent. The relative neurovirulence of the clonal
viruses expressed as the median and 90% lethal dose
is shown in Table 1. The more virulent viruses also
replicated to higher titer in mouse brain.10 In these
initial experiments Clone 2 did not appear to be
attenuated with respect to neurovirulence, but sub-
sequent studies with larger numbers of animals
showed significantly higher survival distribution
compared to Dryvax1 (Figure 1A). To confirm the
attenuated phenotype of Clone 2 virus, two groups
of 6 young adult rhesus monkeys were then inocu-
lated by the intrathalamic route with 7 log10 pfu of
ACAM1000 or Dryvax1. Three (50%) monkeys inocu-
lated with Dryvax1 but none of the animals inocu-
lated with ACAM1000 developed severe neurological
illness. At necropsy, the animals with fatal illness
had severe non-purulent meningitis (Table 2).ne candidates and average survival times (days) at a dose
tracerebral route.
2 mL LD90/0.02 mL Ave survival time
3.0 9.6
1.9 6.1*
<2.3 4.2*
2.1 6.7
2.2 6.9
<1.3 5.0*
3.2 14.4*
4.0 7.9
<1.3 4.1*
2.5 7.8
rvival distribution, log rank test).
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Figure 1 A and B Survival distributions of ACAM1000 and ACAM2000, respectively, compared to negative (diluent)
control and Dryvax1. Groups of 32 suckling mice (4 litters of 8 mice) were inoculated by the intracerebral route with
2.3 log10 Vero cell plaque forming units of each virus in 20 mL or with diluent. The survival distributions of ACAM vaccines
and Dryvax1 are significantly different (p < 0.05, long rank test).
Table 2 Mortality ratio and average clinical scores, monkeys inoculated by the intrathalamic route with ACAM1000 or
Dryvax1 and necropsied on Day 16 after infection.
Study Group (test article) Dose log10
pfu
No.
monkeys
No.
(%) illa
No. (%)
dead
No. (%)
severe histopathologyb
1 ACAM1000 6.0 2 0 (0) 0 (0) 0 (0)
7.0 2 0 (0) 0 (0) 0 (0)
8.0 2 0 (0) 0 (0) 0 (0)
2 ACAM1000 7.1 6 0 (0) 0 (0) 0 (0)
Dryvax1 7.7 6 3 (50) 3 (50) 3 (50)
a A clinical scoring system was used to assign each animal a daily numerical score. Signs of encephalitis, such as paresis,
incoordination, lethargy, tremors or spasticity were assigned numerical values for severity by the following grading method: 0 = No
clinical signs of encephalitis; 1 = Rough coat, not eating; 2 = High pitched voice, inactive, slowmoving; 3 = Shakymovements, tremors,
in coordination, limbweakness; 4 = Inability to stand, limb paralysis, moribund or dead. Animals euthanized due to illness deemed too
severe to permit further observation under humane conditions were given a score of 4 on the day of euthanasia and a score of 4 from
the day after euthanasia through Day 16. Animals that died were given a score of 4 from the day of death to Day 16. The mean clinical
score for each monkey was the average of the animal’s daily score; since animals were evaluated twice daily, the higher daily score
was used. The clinical score for a group was the mean of the individual animal clinical scores. In Study 2, one Dryvax1-treated animal
was found dead on Day 4, and two additional Dryvax1-treated animals underwent unscheduled euthanasia due to declining health
status on Day 6. Clinical signs in these animals included decreased activity levels (observed as low food consumption, decreased
activity, hunched appearance, and/or lethargic), tremors, seizures and convulsions, and loss of coordination. The 3 monkeys that
developed clinical signs had individual mean scores of 3.1, 3.3 and 3.4. The group mean score for this treatment group was 1.8. None
of the ACAM1000 monkeys showed signs of illness, and the group mean score was 0.4.
b Brain sections examined included cerebral cortex, basal ganglia (two levels), thalamus and midbrain, upper medulla and
cerebellum, lower medulla and cerebellum, low medulla, and the cervical and lumbar spinal cord enlargements. Evidence of severe
meningitis was noted histologically in the 3 early death Dryvax1-treated animals in Study 2. Mild signs of residual meningitis, such as
edema and small areas of cellular infiltration (mostly by lymphoid andmonocytic cells), were also noted in the remaining three Group
1 animals and 5/6 Group 2 animals. There was no degeneration or necrosis of neurons, and there were no neuronophagic foci. No
accumulations of bacteria were found in brain sections from animals showing the most severe signs of meningitis, and there were no
signs of demyelination. The characteristics of the neuropathological lesions are consistent with previous studies of vaccinia virus,
which causes nonpurulent meningitis and brain edema in monkeys by, Morita et al.24
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in both mice and nonhuman primates.
Clone 2 (renamed ACAM1000) was selected as the
candidate for further development, based on its
similarity to Dryvax1 in pock formation in rabbit
skin but its lower neurovirulence in mice and mon-
keys. In addition, Weltzin et al.10 reported that
ACAM1000 was similar to Dryvax1 in plaque mor-
phology and HindIII restriction analysis.Preclinical studies of immunogenicity
and protective activity
The immunogenicity of ACAM1000 was studied in
mice and nonhuman primates. Protective activity
was determined in mice challenged with cowpox
and vaccinia Western Reserve (WR) viruses by the
intranasal (IN) route and with ectromelia in mice
challenged by the respiratory route with small par-
ticle aerosols. These studies, some of which have
been published,10 confirmed that ACAM1000 was
similar to Dryvax1 in its ability to induce pock
lesions in mouse or monkey skin, neutralizing anti-
bodies, and Tcell responses, and to protect animals
against lethal challenge. These studies are summar-
ized in Table 3.
Based on these data, a pilot lot of ACAM1000 was
manufactured at clinical grade. The virus was pro-
pagated in MRC-5 cells grown in cell factories,
harvested from the disrupted cells, and purified
by ultrafiltration and diafiltration. A Phase 1 rando-
mized, double-blind clinical trial was conducted in
60 healthy adults aged 18—29 years who had not
previously been vaccinated.10 A second open-label
study was subsequently conducted in 70 subjects.
The results of these Phase 1 trials indicated that
ACAM1000 was well tolerated and immunogenic (see
Clinical Trials).Development of ACAM2000
The requirement to rapidly produce 209 million
doses of vaccine for the US national stockpile cre-
ated a logistical problem for Acambis, which was
still in the process of acquiring large-scale bioreac-
tors for ACAM1000 viral production in MRC-5 cells. To
resolve this problem, Acambis teamed with Baxter
BioScience, which had large-scale production cap-
abilities in its facilities near Vienna, Austria. The
Baxter process utilized a different cell line [African
greenmonkey kidney (Vero)] grown onmicrocarriers
in a 1200 L bioreactor. It was necessary therefore to
pass the ACAM1000 master virus seed in Vero cells
to make a new production virus seed stock at P8(Figure 2). To accommodate the scale of manufac-
ture, an amplification passage (P9) needed to be
introduced to provide sufficient virus to infect cells
in the large bioreactor. Since both the cell substrate
and passage level of the vaccine would change,
molecular, preclinical and clinical bridging studies
would be required to confirm that the new Vero cell
vaccine (named ACAM2000) at P10 was an accepta-
ble vaccine candidate.Method of manufacture and control
tests for adventitious agents
ACAM2000 was manufactured by infecting Vero cells
grown on microcarriers under serum-free conditions
with the P9 production virus inoculum at an MOI of
0.01—0.2. After allowing time for virus replication
(approximately 3 days), the cells are harvested from
the microcarriers and the intracellular virus is
released by mechanical disruption. Cell debris is
removed by large-pore depth filtration. Host cell
DNA is digested with endonuclease (Benzonase1).
Virus particles are subsequently purified and con-
centrated by tangential-flow filtration, followed
by diafiltration. The resulting concentrated bulk
vaccine is formulated by dilution with a buffer con-
taining stabilizers to a final potency of 1.0—
5.0  108 pfu/mL, filled into vials containing
0.3 mL (100 nominal doses), and lyophilized. For
use, the lyophilized vaccine is reconstituted by
addition of diluent [glycerol (50% v/v)-phenol
(0.25% v/v) in water for injection]. Vaccine and
diluent were labeled and packaged in kits containing
50 vials (5000 doses) and supplied with syringes
for diluent transfer for reconstituting vaccine,
and individually wrapped sterile bifurcated needles
for administering vaccine to patients.
Because the original Dryvax1 vaccine from which
ACAM1000 and ACAM2000 was derived had an uncer-
tain provenance and passage history in animal tis-
sue, it was important to subject the seed viruses and
vaccine lots to scrutiny for adventitious agents,
including bacteria, fungi, mycoplasma and viruses.
The approach that was taken to exclude the pre-
sence of detectable adventitious viruses went
beyond compendial requirements (Table 4). To per-
form tests for adventitious viruses in cell cultures
and animals, it was necessary to neutralize the
vaccinia virus with polyclonal and monoclonal anti-
bodies. In addition, seed viruses and vaccine pro-
duced from each bioreactor run were tested for
neurovirulence in suckling mice, using Dryvax1 as
a comparator. Residual Vero cell DNA measured by
hybridization methods in the vaccine product was
below the requirement (10 ng/dose) specified by
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Table 3 Immunogenicity and protective activity of ACAM1000 and Dryvax1 in mice and monkeys.
Study Species
(strain)
Vaccine
(8 log10 pfu/mL)
No. animals Immune response Challenge Survival
Cutaneous
pock N (%)
Neutralizing
antibody N (%)
Neutralizing
antibody titera
IFN-g secreting
cells  1061
1 Mouse (Balb/c) ACAM1000 10 —b 10 (100%) 53 — Cowpox
10 LD50 IN
c
10/10 (100%)
Dryvax1 9 — 5 (56%) 14 — 7/7 (100%)
Sham 5 — 0 (0%) <10 — 0/5 (0%)
2 Mouse (Balb/c) ACAM1000 5 — — — — Vaccinia WR
100 LD50 IN
d
5/5 (100%)
Dryvax1 5 — — — — 5/5 (100%)
Sham 5 — — — — 0/5 (0%)
3 Mouse (Balb/c) ACAM1000 5 — 5 (100%) 92 1450
Dryvax1 5 — 3 (60%) 20 1052
Sham 5 — 0 (0%) <20 0
4 Mouse (Balb/c) ACAM1000 4 — — — — Ectromelia 4.3 log10
pfu aerosol
4/4 (100%)
Dryvax1 4 — — — — 4/4 (100%)
Sham 4 — — — — 0/4 (0%)
5 Monkey (rhesus) ACAM1000 6 6 (100%) 5 (83%) 18 —
Dryvax1 6 6 (100%) 4 (67%) 25 —
a Geometric mean.
b — = not tested.
c 5 weeks after vaccination.
d 3 weeks after vaccination.
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Figure 2 Passage history of ACAM1000 and ACAM2000.WHO. Size analysis by Southern blot showed that the
DNA had been digested into small fragments.Molecular characterization
Since DNA viruses have very low mutation rates
during passage, it was anticipated that the clonal
ACAM1000 and ACAM2000 vaccines would be geneti-
cally and phenotypically conserved. To confirm this,
we fully sequenced the genomes of the ACAM1000
master virus seed (P7, MRC-5 cells) and a represen-
tative lot of ACAM2000 vaccine (P10, 3 passages in
Vero cells beyond the ACAM1000 master virus seed)
(Figure 1). The sequences of ACAM1000 (determined
at St. Louis University) and ACAM2000 (determined
at CDC) were found to be identical (personal com-
munication, J. Esposito et al., CDC, Dec 30, 2003).Biological comparison of ACAM1000 and
ACAM2000
The neurovirulence profiles of ACAM2000 (P10) and
ACAM1000 (P9) vaccines were compared in a lethal
dose assay to Dryvax1 and the virulent Clone 3 virus
recovered from Dryvax1. Groups of eleven 3—4 day-
old outbred ICR mice were inoculated with graded
doses (0.3 to 3.0 log10 pfu) by the IC route. The
median lethal dose (LD50) and 90% lethal dose
(LD90) were higher for mice receiving ACAM2000
and ACAM1000 compared to Dryvax1 and Clone 3
viruses (Table 5). Survival analysis showed that
ACAM1000 and ACAM2000 did not differ from one
another, but had significantly longer survival than
Dryvax1 (p < 0.05, Kaplan Meier survival distribu-
tion, log rank test) (Figure 1B).ACAM2000 (P10), ACAM1000 (P9), and Dryvax1
were each tested in 5 rabbits for cutaneous viru-
lence following percutaneous inoculation of each
virus from 8 to 5 log10 PFU/mL delivered by bifur-
cated needle, as described above (Preclinical
safety in animal models). Central lesions and
erythema produced by ACAM1000 and ACAM2000
did not differ, but both tended to be slightly less
than those evoked by Dryvax1 (Figure 3).
Balb/c mice were immunized by scarification at
the base of the tail with 6 or 8 log10 PFU/mL of
ACAM2000 (P10), ACAM1000 (P9), or Dryvax1 and
neutralizing antibody and T cell responses deter-
mined 3 weeks later. Mean neutralizing antibody
responses following vaccination with ACAM1000
and ACAM2000 were higher than following Dryvax1
at both the high and low doses, but did not differ
significantly (p < .05, Wilcoxon rank sum test) (Fig-
ure 4A). IFN-g secreting cells stimulated with vac-
cinia WR-infected P815 cells were abundant in all
treatment groups (Figure 4B). The specificity of the
Tcell response was also examined using CD8+ splenic
lymphocytes from mice immunized with
8 log10 PFU/mL and depleted of B cells, CD4
+ cells,
macrophages, and NK cells using monoclonal anti-
body-conjugated magnetic beads and magnetic cell
sorting. Strong CD8+ responses were seen in all
three treatment groups but not in unimmunized
controls, and there were no statistical differences
in responses across the vaccine treatment groups
(data not shown).
To compare the protective efficacy of immuniza-
tion with ACAM2000, ACAM1000, and Dryvax1,
groups of 5 young adult BALB/c mice were immu-
nized with graded doses (4 to 7 log10 PFU/mL) of
the different viruses and then challenged by the
IN route 3 weeks later with 100 LD50 of vaccinia
WR virus. Survival and body weight were recorded
daily for 14 days after challenge. Protective
efficacy of the 3 viruses tested was similar. The
survival times were not statistically different
between treatment groups (p < 0.05, Kaplan—Meier
survival distribution, log rank test). Doses required
for protection of 50% of mice from death were
also similar for ACAM1000 (5.4 log10 PFU/mL),
ACAM2000 (5.6 log10 PFU/mL) and Dryvax
1
(5.2 log10 PFU/mL).Clinical trials
Clinical development was initiated with a pilot lot of
ACAM1000. The first trial was a randomized, double-
blind study in healthy adults aged 18—29 years, and
has been reported by Weltzin et al.10 Briefly, all 30
subjects (100%, 95% CI 88, 100) inoculated with
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Table 4 Tests performed to control ACAM2000 for adventitious agents (blank spaces in the table indicate that the test
was not performed).
Description of Test Method Master
Virus Seed (ACAM
1000/2000) P7
Production
Virus Seed
(ACAM2000) P8
Vaccine lot
(ACAM2000)
P10
Sterility Culture for
bacteria and fungi
X X X
Mycobacteria 42-day guinea
pig test
X
Mycoplasma Cultivation Method X X X
Polymerase chain
reaction (PCR), agar
cultivatable and non-cultivatable
X X X
Adventitious Virus
(general)
In vitro virus assay
(Vero, MRC-5, and
either HeLa and
RK cells or A9 cells)
X X X
Adventitious Virus
(general)
In vivo virus assay
(suckling and adult mice,
guinea pigs, embryonated eggs)
X X X
Adventitious virus
(animal)
Bovine viral diarrhea (PCR) X X Xa
Bovine viral diarrhea
(in vitro infectivity)
X
Bovine parainfluenza
type 3 (PCR)
X X Xa
Bovine respiratory
syncytial virus (PCR)
X X Xa
Bovine adenovirus (PCR) X X Xa
Bovine parvovirus (PCR) X X Xa
Porcine parvovirus (PCR) X Xa
Bovine herpes virus-I
(bovine rhinotracheitis) and
bovine herpes-IV (PCR)
X Xa
Bovine reovirus (PCR) X Xa
Rabies virus (PCR) X Xa
Bluetongue virus (PCR) X Xa
Bovine polyoma virus (PCR) X X Xa
Adventitious Viruses
(human)
HIV 1 and 2 (PCR) X X Xa
Hepatitis B (PCR) X X Xa
Cytomegalovirus (PCR) X X Xa
Epstein Barr Virus (PCR) X X Xa
Human herpesvirus
type 6 (PCR)
X X Xa
Human herpesvirus
type 7 (PCR)
X X Xa
Human herpesvirus
type 8 (PCR)
X Xa
Hepatitis C (PCR) X X Xa
HTLV I and II (PCR) X X Xa
Parvovirus B19 (PCR) X X Xa
Reovirus (PCR) X Xa
JC/BK virus (PCR) X Xa
SV40 virus (PCR) X Xa
Coronavirus (PCR) X Xa
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Table 4 (Continued )
Description of Test Method Master
Virus Seed (ACAM
1000/2000) P7
Production
Virus Seed
(ACAM2000) P8
Vaccine lot
(ACAM2000)
P10
Human Papilloma Virus (PCR) X Xa
Hepatitis A virus (PCR) X Xa
Enterovirus (PCR) X Xa
Influenza C (PCR) X Xa
Human parainfluenza
types 1, 2, 3 (PCR)
X Xa
Human respiratory syncytial
virus Types A and B (PCR)
X Xa
Retrovirus (f-PERT) X X
a Performed on three successive lots to demonstrate consistent freedom from adventitious agents.ACAM1000 and 29 of 30 subjects (97%, 95% CI 83,
100) inoculated with Dryvax1 developed a major
cutaneous reaction7days after vaccination (Table 6).
The same proportions of subjects in each treatment
group developed neutralizing antibodies (p = 1.000,
Fisher’s exact test). The geometric mean neutraliz-
ing antibody titers in the ACAM1000 and Dryvax1
groups of 142 and 248, respectively, were not
statistically different (p = 0.181, ANOVA). T cell
responses were measured by cytotoxic T cell assay,
IFN-g ELISPOT, and lymphoproliferation.10 T cell
responses were seen to both vaccines in the vast
majority of subjects (Table 6). In the lymphoproli-
feration assay, ACAM1000 responses were signifi-
cantly higher than in the Dryvax1 group. The
adverse event profile of ACAM1000 and Dryvax1
were also similar (Table 7).
These clinical results suggested that ACAM1000
was a suitable candidate smallpox vaccine. How-
ever, the Phase 1 study had been conducted within 6
months of the events of September 11, and there
was grave concern about bioterrorism. The question
arose as to how much clinical data should be avail-
able with the new vaccine to allow its wider use in
an emergency. It was determined in meetings with
US Government officials, that clinical data from a
minimum of 100 subjects should be available.
Therefore, to bring the total number to 100 sub-
jects, a second study was performed. This secondTable 5 Median Lethal Dose (LD50) of ACAM1000,
ACAM2000, Dryvax1, and Clone 3 in Mice.
Virus LD50
a LD90
b
ACAM2000 1.6 2.9
ACAM1000 2.6 >3.3
Dryvax1 0.8 2.2
Clone 3 <0.3 1.1
a 50% IC lethal dose (log10) per 0.02 mL inoculum.
b 90% IC lethal dose (log10) per 0.02 mL inoculum.Phase 1, open-label study was designed to evaluate
the safety, tolerability, and immunogenicity of
ACAM1000 smallpox vaccine in 70 adults aged 18
to 29 years, inclusive, who were naı¨ve to smallpox
vaccine, and enrolled in the study at a single study
center in the United States. Eligible subjects and
their household contacts had no contraindications
to smallpox vaccination (atopic dermatitis, other
active skin diseases, immune deficiency, preg-
nancy). Safety was assessed by documentation of
adverse events, physical examination findings,
lymph node assessments, measurements of vital
signs, and clinical laboratory tests, including hema-
tology, clinical chemistry, and urinalysis. Eligible
subjects who provided informed consent received
a single vaccination with ACAM1000. Subjects
returned to the clinic on Days 3, 7, 10, 15, and 30
for evaluations and also kept a diary of adverse
events and took daily oral temperatures. Fifty-one
percent of subjects were male. The majority (87%)
were Caucasian. All 70 subjects (100%) experiencedFigure 3 The central lesion resulting from graded doses
of ACAM1000 or ACAM2000 was compared to the lesion
caused by the equivalent dose of Dryvax1 in the same
rabbit, and the difference in lesion diameter was deter-
mined.
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Figure 4 (A) Neutralizing antibody responses following
immunization of mice with ACAM2000, ACAM1000, or
Dryvax1. (B) T Cell responses following immunization of
mice with ACAM2000, ACAM1000, or Dryvax1. Secretion of
interferon-g by splenic lymphocytes stimulated by vacci-
nia virus in vitro.
Table 6 Immunogenicity, ACAM1000 and ACAM2000, Phase
Statistic Study
H-300-
ACAM1
Number of subjects 30
Major cutaneous reaction
No. (%) 30 (10
95% Confidence interval 88, 10
Maximum lesion size (mm)
Central lesion, mean (SD) 13.4 (
Erythema, mean (SD) 25.8 (
Seroconversion, neutralizing antibodies
No. (%) 30 (10
Neutralizing antibodies, Geometric Mean Titer 142
T cell response No. pos/tested (%)
Cytotoxic T lymphocyte 24/29
g-Interferon ELISPOT 29/29
Lymphoproliferation 28/29a successful vaccination (major cutaneous reaction)
by Day 7—10 after vaccination. Seroconversion
(fourfold increase in neutralizing antibody titer
by Day 30) was demonstrated in 66 (94%) of the
subjects (Table 6). The geometric mean neutralizing
antibody titer on Day 30 was 154; the titer varied
considerably, ranging from 20 to 20,480. The evolu-
tion of lesions and size of the pock lesions were
similar to those observed in the first trial, with a
papule or vesicle appearing on Day 3, progressing to
a pustular lesion by Day 7 and scabbing over in the
majority of cases by Day 15. There were no serious
adverse events. All 70 subjects (100%) experienced
at least one treatment-emergent, expected adverse
event during the study (Table 7). Overall, the most
commonly reported adverse events were related to
the inoculation site. The adverse events were gen-
erally mild and did not interfere with the subjects’
daily activities.
Clinical development of ACAM2000 commenced
with a Phase 1 open-label trial in 100 healthy adults
aged 18—29 years old without prior smallpox vacci-
nation. Exclusion and inclusion criteria were the
same as for the ACAM1000 study described above.
The primary endpoint was the proportion of subjects
with a major cutaneous reaction assessed at any
time-point from Day 7 (2) through Day 15 (2).
Fifty-six percent of subjects were male. The major-
ity (89%) were Caucasian; the remaining subjects
were African-American (7%), Asian (3%), or Hispanic
(1%). The mean age was 23 years, with a range of 18
to 29 years.1 clinical trials.
number/Study vaccine
001 H-300-003 H-400-008
000 Dryvax1 ACAM1000 ACAM2000
30 70 100
0) 29 (97) 70 (100) 99 (99)
0 83, 100 95, 100 95, 100
1.87) 12.6 (2.37) 10.9 (1.76) 10.3 (1.83)
8.52) 30.7 (16.09) 22.8 (15.79) 35.7 (17.32)
0) 29 (97) 66 (94) 96 (96)
248 154 225
(80) 26/30 (90) Not tested Not tested
(100) 29/30 (97)
(97) 21/30 (70)
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Table 7 Treatment-emergent adverse events (AE) reported by 5% of subjects.
Study No. and treatment
H-300-001 H-300-003 H-400-008
ACAM1000
(n = 30) n (%)
Dryvax1
(n = 30) n (%)
ACAM1000
(n = 70) n (%)
ACAM2000
(n = 100) n (%)
Subjects with at least 1 AE 30 (100) 30 (100) 70 (100) 100 (100)
Injection site erythema 29 (97) 28 (93) 70 (100) 100 (100)
Injection site pruritus 19 (63) 15 (50) 62 (89) 97 (97)
Injection site pain 24 (80) 27 (90) 50 (71) 67 (67)
Lymph node or axillary pain 22 (73) 19 (63) 50 (71) 67 (67)
Headache NOS 18 (60) 18 (60) 36 (51) 46 (46)
Fatigue 6 (20) 9 (30) 28 (40) 45 (45)
Lymphadenopathy 5 (17) 7 (23) 16 (23) 40 (40)
Injection site inflammation 24 (80) 25 (83) 58 (83) 37 (37)
Myalgia 8 (27) 9 (30) 22 (31) 38 (38)
Malaise 5 (17) 4 (13) 17 (24) 38 (38)
Feeling hot 11 (37) 13 (43) 11 (16) 31 (31)
Rigors 5 (17) 6 (20) 12 (17) 18 (18)
Nausea 1 (3) 2 (7) 11 (16) 13 (13)
Diarrhea NOS 2 (7) 1 (3) 7 (10) 11 (11)
Body temperature increased 1 (3) 5 (17) 4 (6) 9 (9)
Cough 1 (3) 2 (7) 0 5 (5)
Upper respiratory tract infection 5 (17) 3 (10) 3 (4) 4 (4)
White blood cells urine positive 3 (10) 5 (17) 5 (7) 4 (4)
Pharyngitis 3 (10) 3 (10) 4 (6) 4 (4)
Nasal congestion 0 4 (13) 1 (1) 3 (3)
Rash NOS 3 (10) 4 (13) 6 (9) 2 (2)
Injection site burning 3 (10) 1 (3) 1 (1) 1 (1)
Abdominal pain upper 1 (3) 2 (7) 0 1 (1)
Dizziness 1 (3) 2 (7) 2 (3) 0
Application site irritation 1 (3) 2 (7) 0 0
Neck stiffness 2 (7) 0 0 0
NOS = Not otherwise specified.
Figure 5 Progression of cutaneous lesion in healthy
adults without previous smallpox vaccination who were
inoculated with ACAM2000.Ninety-nine percent of the subjects experienced
a successful vaccination in this study (Table 6). Of
the 99 subjects who experienced a major cutaneous
reaction, 9% had a major cutaneous reaction by Day
3, and the rest experienced a major cutaneous
reaction by Day 7. The progression of the cutaneous
reaction (Figure 5) and its size and appearance were
similar to those observed in the trials of ACAM1000
(data not shown). The great majority (96%) devel-
opedfourfold increases in neutralizing antibodies.
The geometric mean neutralizing antibody titer on
Day 30 was 225. Four (4%) of 100 subjects did not
have a fourfold increase in neutralizing antibody
titer on Day 30. However, these 4 subjects all had
amajor cutaneous reaction by Day 7. This illustrated
that local replication in the skin and development of
a pock is not invariably accompanied by a systemic
humoral immune response detectable by a 50%
plaque-reduction neutralization test.
One subject experienced a serious adverse event,
a single new onset seizure on Day 8; this event was
considered by the Investigator to be remotelyrelated to the study vaccine. All 100 (100%) subjects
experienced at least 1 treatment-emergent adverse
event during the study. The most commonly
reported treatment-emergent adverse events were
related to the vaccination site and associated lym-
phadenitis (Table 7), and the majority of adverse
events reported were assessed as mild or moderate
in intensity. No notable changes from Screening to
S42 T.P. Monath et al.Day 15 were seen in any hematologic or clinical
chemistry parameter. Minimal changes in mean oral
temperature were observed. Elevated temperature
was reported as an adverse event for 9 (9%) sub-
jects. Of these 9 subjects, 1 subject with concurrent
streptococcal pharyngitis had a body temperature
>38.9 8C during the study. For the remaining sub-
jects, body temperature was <38.9 8C at all time-
points assessed. Lymph node enlargement and/or
tenderness was present on at least 1 post-vaccina-
tion time-point for 61 (61%) of 100 subjects.Discussion
It has long been recognized that vaccinia virus
represents a heterogeneous swarm of virus subpo-
pulations that differ biologically and molecularly.11
This variation became especially important as vac-
cinia was developed as a live vector for foreign
genes. Plaque-purified vaccinia virus lines were
shown to differ significantly in neurovirulence for
mice, in their ability to evoke immune responses
against the inserted gene product, and in their
HindIII restriction maps.12,13 From virus stocks that
underwent serial passages, variants could be recov-
ered that contained deletions within or extending
beyond the inverted terminal repeat regions,14—17
some of which were as large as 9 MDa (5% of the
genome). The variant viruses often exhibit reduced
infectivity and reduced virulence for mice.18 Similar
deletion variants have been reported for other
orthopoxviruses, including cowpox and monkeypox.
It is not surprising, therefore, that we found biolo-
gical and molecular heterogeneity among 6 clones
derived from Dryvax1, with some clonal subpopula-
tions (e.g. Clone 3) having dramatically higher viru-
lence10 and changes at the genomic level (Esposito J
pers. comm.). Clone 3 derived from Dryvax1 was
shown to have an altered HindIII restriction map10
and to contain a deletion at the right terminus and
hundreds of mutations compared to the attenuated
ACAM2000 (Clone 2). These observations were
important when considering development of the
second generation cell culture vaccine. The produc-
tion of vaccine at a large scale in cell culture would
put selective pressure on the virus, resulting in a
different ratio of virion subpopulations in the end
product compared to that in the original calf-skin
vaccine. Indeed, we found that passage of uncloned
Dryvax1 in MRC-5 cells yielded a vaccine candidate
that was unacceptably virulent. Such selective pres-
sures could be inconsistent across vaccine lots made
at large scale, with resulting variability in biological
phenotype, and lot-to-lot differences in tests used
to release the product.The clinical relevance of virus heterogeneity in
first generation smallpox vaccines is uncertain.
However, there is reason to believe that a well-
defined clonal product has advantages. Ehrengut
et al.19,20 recovered vaccinia virus from patients
who had dermatologic (vaccinia ulcer) or neurolo-
gical complications. The viruses isolated from the
affected patients differed from the parental vac-
cine in being resistant to high temperature, growing
to higher titer in cell culture, producing larger
plaque sizes, and causing marked necrosis in
rabbit skin after intradermal inoculation. Similarly,
Vilesova et al.21 studied 6 virus isolates from cere-
brospinal fluid and brain tissue of patients with
post-vaccinal encephalitis. These strains were also
thermostable, exhibited larger plaque size in cell
culture, and were more pathogenic for chick
embryos and more dermovirulent in rabbits than
the parental vaccine. These data suggest that selec-
tion of a virulent virus subpopulation can occasion-
ally occur during replication in the vaccinated host,
leading to neurological or dermal complications.
The degree of neurovirulence for suckling mice
was used by Marrenikova21,22 to distinguish vaccine
strains with low, moderate, or high pathogenicity.
This classification by toxicity for mice correlated
with the incidence of post-vaccinal encephalitis in
human populations exposed to the corresponding
vaccine strains22—24. For example, vaccines with
high mouse pathogenicity, such as the Temple of
Heaven and Tashkent strains, were associated with
high incidence rates of post-vaccinial encephalitis,
whereas the New York City Board of Health (NYCBH)
strain (e.g. Dryvax1) was associated with the lowest
rates of this complication. The Lister strain, widely
used in Europe and elsewhere, is of moderate mouse
pathogenicity, and may have caused a higher rate of
neurological complications than NYCBH in humans.
We showed that ACAM1000 and ACAM2000 were
significantly less neurovirulent for mice and mon-
keys than the parental Dryvax1 virus, presumably
because it contains neurovirulent virus subpopula-
tions exemplified by Clones 1, 3 and 5. It is logical to
assume, based on the discussion above, that
ACAM2000 will be less likely to cause post-vaccinal
encephalitis in humans. However, since the inci-
dence of this complication following Dryvax1 vac-
cination is so low (in the range of 1—5 permillion1,2),
it would not be possible to prove this contention in
clinical trials. Moreover, the pathogenesis of post-
vaccinal encephalitis is still uncertain, with contro-
versy regarding the role of neuroinvasion and direct
viral injury, particularly in cases of post-vaccinial
encephalitis in adults. Vaccinia virus has been iso-
lated from CSF and brain,25,26 suggesting that the
virus invades the central nervous system in humans.
A second-generation smallpox vaccine for biological defense S43The events that follow could have an immunopatho-
logical component, leading to destruction ofmyelin.
Animal models (mice, monkeys) mimic the early-
onset edematous form of meningoencephalitis
observed more frequently in infants,27,28 but do
not show perivenous demyelination typical of the
adult form of the disease, which clinically resembles
acute disseminated encephalomyelitis (ADEM) and
suggests a parainfectious (immunopathological) dis-
ease process.
Phase 1 clinical trials of ACAM1000 and 2000
indicate that the original goal of producing a second
generation vaccine that closely matched the safety
and immunogenicity of calf-skin vaccine (Dryvax1)
was met. The cutaneous, antibody, and T cell
responses in primary vaccinees were similar to those
elicited by Dryvax1. The appearance (Figure 5) and
size of the cutaneous lesion and pattern of virus
shedding from the vaccination site were also similar.
Phase 2 trials in naı¨ve and previously vaccinated
subjects have been completed to define the dose
response, and to extend safety and immunogenicity
data.29 Phase 3 clinical trials are in progress. The
principal finding of concern in Phase 2 and 3 trials
involving larger numbers of subjects has been the
discovery that smallpox vaccines are associated
with inflammation of the myocardium and pericar-
dium (myopericarditis).30,31 Althoughmyopericardi-
tis had been reported previously, it had not been
recognized as a frequent complication of vaccina-
tion. In clinical trials of ACAM2000 and Dryvax1,
myopericarditis has been associated with both vac-
cines, and appears to be an immunopathological
response to vaccinia infection. The military experi-
ence with Dryvax1 suggests that the incidence of
myopericarditis detected by passive surveillance
approximates 1:8000.30 A significantly higher inci-
dence is being detected in our Phase 3 clinical trials,
since subjects are evaluated prospectively with
provoked questions for cardiac symptoms and with
serial electrocardiograms and serum enzyme tests.
Fortunately, the cardiac adverse events appear to
be self-limited. These data will be reported in
future publications.
In summary, ACAM2000 appears to be a suitable
vaccine for prevention of smallpox. The similar
immune responses in humans and protective activity
in animals to the currently licensed Dryvax1 vaccine
(which was used in the global program to eradicate
smallpox) provide confidence that the vaccine will
protect against variola. The new vaccine has advan-
tages over first generation vaccines, since it has
been produced to modern manufacturing and con-
trol standards, is free from adventitious agents
(Table 5), and does not contain subpopulations of
virus with undesirable virulence properties. It is alsoa ‘very low pathogenicity’ strain, being less
neurovirulent for animals than Dryvax1. The latter
property may be associated with a lower propensity
to cause post-vaccinial encephalitis, but this pro-
position cannot be proven without very wide-scale
use of the vaccine to evaluate incidence rates.Acknowledgements
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